Edesa Biotech Statistics
Total Valuation
Edesa Biotech has a market cap or net worth of $13.54 million. The enterprise value is $10.80 million.
Market Cap | 13.54M |
Enterprise Value | 10.80M |
Important Dates
The next estimated earnings date is Wednesday, August 7, 2024, after market close.
Earnings Date | Aug 7, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Edesa Biotech has 3.22 million shares outstanding. The number of shares has increased by 11.89% in one year.
Shares Outstanding | 3.22M |
Shares Change (YoY) | +11.89% |
Shares Change (QoQ) | +2.07% |
Owned by Insiders (%) | 34.07% |
Owned by Institutions (%) | 10.66% |
Float | 2.25M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 3.13 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.97, with a Debt / Equity ratio of 0.01.
Current Ratio | 1.97 |
Quick Ratio | 1.82 |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -115.60% and return on invested capital (ROIC) is -194.22%.
Return on Equity (ROE) | -115.60% |
Return on Assets (ROA) | -88.90% |
Return on Capital (ROIC) | -194.22% |
Revenue Per Employee | n/a |
Profits Per Employee | -$452,814 |
Employee Count | 16 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Edesa Biotech has paid $800 in taxes.
Income Tax | 800 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.14% in the last 52 weeks. The beta is 0.87, so Edesa Biotech's price volatility has been lower than the market average.
Beta (5Y) | 0.87 |
52-Week Price Change | -28.14% |
50-Day Moving Average | 4.44 |
200-Day Moving Average | 4.38 |
Relative Strength Index (RSI) | 43.31 |
Average Volume (20 Days) | 8,772 |
Short Selling Information
The latest short interest is 15,792, so 0.49% of the outstanding shares have been sold short.
Short Interest | 15,792 |
Short Previous Month | 14,792 |
Short % of Shares Out | 0.49% |
Short % of Float | 0.70% |
Short Ratio (days to cover) | 1.19 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -8.51M |
Pretax Income | -7.24M |
Net Income | -7.25M |
EBITDA | -7.02M |
EBIT | -7.24M |
Earnings Per Share (EPS) | -$2.37 |
Balance Sheet
The company has $2.80 million in cash and $58,143 in debt, giving a net cash position of $2.74 million or $0.85 per share.
Cash & Cash Equivalents | 2.80M |
Total Debt | 58,143 |
Net Cash | 2.74M |
Net Cash Per Share | $0.85 |
Equity (Book Value) | 4.32M |
Book Value Per Share | 1.34 |
Working Capital | 2.09M |
Cash Flow
Operating Cash Flow | -6.34M |
Capital Expenditures | n/a |
Free Cash Flow | -6.34M |
FCF Per Share | -$1.99 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Edesa Biotech does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -11.89% |
Shareholder Yield | -11.89% |
Earnings Yield | -53.51% |
FCF Yield | -46.83% |
Analyst Forecast
The average price target for Edesa Biotech is $39.00, which is 826.37% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $39.00 |
Price Target Difference | 826.37% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on October 11, 2023. It was a reverse split with a ratio of 1:7.
Last Split Date | Oct 11, 2023 |
Split Type | Reverse |
Split Ratio | 1:7 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |